All In Biotech

Drug Trial Radar · NCT00278941

Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder

A Multi-Centre, Double-Blind, Randomised-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) As Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Mar 25, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,000

Actual

Start

Dec 2005

Primary completion

Not stated

Study completion Aug 2007

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep, overall quality of life, and effect, if any, on anxiety and satisfaction PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Conditions

  • Major Depressive Disorder

Interventions

  • Quetiapine Fumarate Sustained ReleaseDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to a depressed event in patients with Major Depressive Disorder (MDD)

Locations

168 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Tuscaloosa, Alabama

  • Research Site

    Mesa, Arizona

  • Research Site

    Peoria, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Cerritos, California

  • Research Site

    Costa Mesa, California

  • Research Site

    El Centro, California

  • Research Site

    Fresno, California

  • Research Site

    La Mesa, California

  • Research Site

    Los Angeles, California

  • Research Site

    Oceanside, California

  • Research Site

    Pasadena, California

  • Research Site

    Pico Rivera, California

  • Research Site

    Redlands, California

  • Research Site

    Riverside, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Ana, California

  • Research Site

    Stanford, California

  • Research Site

    Torrance, California

  • Research Site

    Upland, California

  • Research Site

    Vista, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Pueblo, Colorado

  • Research Site

    Cromwell, Connecticut

  • Research Site

    Farmington, Connecticut

  • Research Site

    Middletown, Connecticut

  • Research Site

    Wilmington, Delaware

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Altamonte Springs, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Fort Myers, Florida

  • Research Site

    Gainsville, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.